Elan Corp, plc (ADR) (NYSE:ELN)

CAPS Rating: 3 out of 5

The Company's Biopharmaceuticals unit is engaged in research, development and commercial activities and its EDT unit focuses on product development, scale-up and manufacturing to address drug optimization challenges of the pharmaceutical industry.

Recs

0
Player Avatar buckoblue31 (< 20) Submitted: 10/30/2010 12:15:41 AM : Outperform Start Price: $5.44 ELN Score: +151.92

Company has excelled in the past with it's tenacious performance with most of its trials. This kind of tynasity canot go unrewarded for to long a period.

Featured Broker Partners


Advertisement